Alemtuzumab on its way to approval in MS
Paris - Sanofi and MS patients can breathe a sigh of relief. At an MS congress in Amsterdam, the company presented impressive results of a phase III trial comparing alemtuzumab with subcutaneous Rebif interferon beta-1a in 581 treatment-naive patients with relapsing-remitting multiple sclerosis (RRMS). 78% of these patients treated with the monoclonal antibody remained free from relapse after two years, compared with a 59% quota with Rebif. Rebif is marketed by Merck Serono and Pfizer. Alemtuzumab also met the secondary endpoint of a greater improvement in mean Multiple Sclerosis Functional Composite (MSFC) scores from baseline to two years vs. Rebif, but missed the secondary endpoint of reducing median T2 hyperintense MAAs for alemtuzumab in the U.S. and EU in the first quarter of 2012.